Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts

被引:3
|
作者
Lee, Rex H. [1 ]
Roy, Ritu [2 ]
Li, Hua [1 ]
Hechmer, Aaron [2 ]
Zhu, Tian Ran [1 ]
Izgutdina, Adila [1 ]
Olshen, Adam B. [2 ,3 ]
Johnson, Daniel E. [1 ]
Grandis, Jennifer R. [1 ]
机构
[1] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
来源
PLOS ONE | 2023年 / 18卷 / 03期
基金
美国国家卫生研究院;
关键词
HUMAN-PAPILLOMAVIRUS; REPAIR; HPV;
D O I
10.1371/journal.pone.0282177
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
There are currently no clinical strategies utilizing tumor gene expression to inform therapeutic selection for patients with head and neck squamous cell carcinoma (HNSCC). One of the challenges in developing predictive biomarkers is the limited characterization of preclinical HNSCC models. Patient-derived xenografts (PDXs) are increasingly recognized as translationally relevant preclinical avatars for human tumors; however, the overall transcriptomic concordance of HNSCC PDXs with primary human HNSCC is understudied, especially in human papillomavirus-associated (HPV+) disease. Here, we characterized 64 HNSCC PDXs (16 HPV+ and 48 HPV-) at the transcriptomic level using RNA-sequencing. The range of human-specific reads per PDX varied from 64.6%-96.5%, with a comparison of the most differentially expressed genes before and after removal of mouse transcripts revealing no significant benefit to filtering out mouse mRNA reads in this cohort. We demonstrate that four previously established HNSCC molecular subtypes found in The Cancer Genome Atlas (TCGA) are also clearly recapitulated in HNSCC PDXs. Unsupervised hierarchical clustering yielded a striking natural division of HNSCC PDXs by HPV status, with C19orf57 (BRME1), a gene previously correlated with positive response to cisplatin in cervical cancer, among the most significantly differentially expressed genes between HPV+ and HPV- PDXs. In vivo experiments demonstrated a possible relationship between increased C19orf57 expression and superior anti-tumor responses of PDXs to cisplatin, which should be investigated further. These findings highlight the value of PDXs as models for HPV+ and HPV- HNSCC, providing a resource for future discovery of predictive biomarkers to guide treatment selection in HNSCC.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient-derived xenografts
    Rab, Regina
    Ehrhardt, Annette
    Achyut, Bhagelu R.
    Joshi, Disha
    Gilbert-Ross, Melissa
    Huang, Chunzi
    Floyd, Katharine
    Borovjagin, Anton, V
    Parker, William B.
    Sorscher, Eric J.
    Hong, Jeong S.
    CANCER REPORTS, 2023, 6 (02)
  • [42] mTOR inhibition with everolimus - a novel treatment option for head and neck cancer identified in a translational research study using patient-derived xenografts
    Klinghammer, K.
    Raguse, J. D.
    Plath, T.
    Albers, A. E.
    Brzezicha, B.
    Wulf-Goldenberg, A.
    Keilholz, U.
    Hoffmann, J.
    Fichtner, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 10 - 10
  • [43] Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib
    Hu, Fangling
    Guo, Liang
    Yu, Jieqing
    Dai, Daofeng
    Xiong, Yuanping
    He, Yuanqiao
    Zhou, Wensheng
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [44] Excavation of therapeutic targets based on the molecular signature of patient-derived tumor xenografts in gastric cancer
    Chen, Zuhua
    Gao, Jing
    Shen, Lin
    CANCER RESEARCH, 2017, 77
  • [45] Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response
    Zhang, Feifei
    Wang, Wenjie
    Long, Yuan
    Liu, Hui
    Cheng, Jijun
    Guo, Lin
    Li, Rongyu
    Meng, Chao
    Yu, Shan
    Zhao, Qingchuan
    Lu, Shun
    Wang, Lili
    Wang, Haitao
    Wen, Danyi
    CANCER COMMUNICATIONS, 2018, 38 : 1 - 12
  • [46] Patient-derived xenografts (PDXs) as model systems for human cancer
    Invrea, Federica
    Rovito, Roberta
    Torchiaro, Erica
    Petti, Consalvo
    Isella, Claudio
    Medico, Enzo
    CURRENT OPINION IN BIOTECHNOLOGY, 2020, 63 : 151 - 156
  • [47] Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer
    Porter, Laura H.
    Lawrence, Mitchell G.
    Wang, Hong
    Clark, Ashlee K.
    Bakshi, Andrew
    Obinata, Daisuke
    Goode, David
    Papargiris, Melissa
    Mural
    Clouston, David
    Ryan, Andrew
    Norden, Sam
    Corey, Eva
    Nelson, Peter S.
    Isaacs, John T.
    Grummet, Jeremy
    Kourambas, John
    Sandhu, Shahneen
    Murphy, Declan G.
    Pook, David
    Frydenberg, Mark
    Taylor, Renea A.
    Risbridger, Gail P.
    PROSTATE, 2019, 79 (11): : 1326 - 1337
  • [48] Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts
    Bani, MariaRosa
    Ghilardi, Carmen
    Decio, Alessandra
    Anastasia, Alessia
    Verza, Martina
    Indraccolo, Stefano
    Giavazzi, Raffaella
    CANCER RESEARCH, 2018, 78 (13)
  • [49] The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer
    Lewis, Michael T.
    Caldas, Carlos
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2024, 14 (04):
  • [50] Establishment of patient-derived cancer xenografts in immunodeficient NOG mice
    Chijiwa, Tsuyoshi
    Kawai, Kenji
    Noguchi, Akira
    Sato, Hidemitsu
    Hayashi, Akimune
    Cho, Haruhiko
    Shiozawa, Manabu
    Kishida, Takeshi
    Morinaga, Soichiro
    Yokose, Tomoyuki
    Katayama, Makoto
    Takenaka, Nobuo
    Suemizu, Hiroshi
    Yamada, Roppei
    Nakamura, Yoshiyasu
    Ohtsu, Takashi
    Takano, Yasuo
    Imai, Kohzoh
    Miyagi, Yohei
    Nakamura, Masato
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 61 - 70